A citation-based method for searching scientific literature

Rafael Luís, Cheila Brito, Marta Pojo. Adv Exp Med Biol 2020
Times Cited: 9







List of co-cited articles
22 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Current Advances in the Treatment of BRAF-Mutant Melanoma.
Hima Patel, Nour Yacoub, Rosalin Mishra, Aaron White, Yuan Long, Samar Alanazi, Joan T Garrett. Cancers (Basel) 2020
42
22

Cancer immunoediting and resistance to T cell-based immunotherapy.
Jake S O'Donnell, Michele W L Teng, Mark J Smyth. Nat Rev Clin Oncol 2019
367
22

From melanocyte to metastatic malignant melanoma.
Bizhan Bandarchi, Linglei Ma, Roya Navab, Arun Seth, Golnar Rasty. Dermatol Res Pract 2010
75
22

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Tuba N Gide, James S Wilmott, Richard A Scolyer, Georgina V Long. Clin Cancer Res 2018
128
22

Targeted Therapy for Melanoma.
Deborah J L Wong, Antoni Ribas. Cancer Treat Res 2016
63
22

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Chune Yu, Xiaowei Liu, Jiqiao Yang, Min Zhang, Hongyu Jin, Xuelei Ma, Hubing Shi. Front Immunol 2019
42
22

ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway.
Sarah E Tague, Vandhana Muralidharan, Crislyn D'Souza-Schorey. Proc Natl Acad Sci U S A 2004
134
22

Update in genetic susceptibility in melanoma.
Miriam Potrony, Celia Badenas, Paula Aguilera, Joan Anton Puig-Butille, Cristina Carrera, Josep Malvehy, Susana Puig. Ann Transl Med 2015
89
22

ARF proteins: roles in membrane traffic and beyond.
Crislyn D'Souza-Schorey, Philippe Chavrier. Nat Rev Mol Cell Biol 2006
965
22

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Antonio M Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella, Martina Strudel, Paolo A Ascierto. Am J Clin Dermatol 2017
56
22

Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.
Kathleen A Cronin, Andrew J Lake, Susan Scott, Recinda L Sherman, Anne-Michelle Noone, Nadia Howlader, S Jane Henley, Robert N Anderson, Albert U Firth, Jiemin Ma,[...]. Cancer 2018
563
22

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, Rene Gonzalez, Anna C Pavlick, Jeffrey S Weber, Grant A McArthur, Thomas E Hutson, Stergios J Moschos, Keith T Flaherty,[...]. N Engl J Med 2012
22

Melanoma treatment in review.
Beatriz Domingues, José Manuel Lopes, Paula Soares, Helena Pópulo. Immunotargets Ther 2018
211
22

The Ras protein superfamily: evolutionary tree and role of conserved amino acids.
Ana Maria Rojas, Gloria Fuentes, Antonio Rausell, Alfonso Valencia. J Cell Biol 2012
225
22

Current concepts of metastasis in melanoma.
Blazej Zbytek, J Andrew Carlson, Jacqueline Granese, Jeffrey Ross, Martin C Mihm, Andrzej Slominski. Expert Rev Dermatol 2008
138
22

The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective.
Cristina Casalou, Andreia Ferreira, Duarte C Barral. Front Cell Dev Biol 2020
12
22


Arl13b Regulates Breast Cancer Cell Migration and Invasion by Controlling Integrin-Mediated Signaling.
Cristina Casalou, Alexandra Faustino, Fernanda Silva, Inês C Ferreira, Daniela Vaqueirinho, Andreia Ferreira, Pedro Castanheira, Teresa Barona, José S Ramalho, Jacinta Serpa,[...]. Cancers (Basel) 2019
5
40

ARF GTPases and their GEFs and GAPs: concepts and challenges.
Elizabeth Sztul, Pei-Wen Chen, James E Casanova, Jacqueline Cherfils, Joel B Dacks, David G Lambright, Fang-Jen S Lee, Paul A Randazzo, Lorraine C Santy, Annette Schürmann,[...]. Mol Biol Cell 2019
70
22

ARLTS1 variants and melanoma risk.
Bernd Frank, Peter Meyer, Melanie Barbara Boettger, Kari Hemminki, Henrike Stapelmann, Andreas Gast, Christina Schmitt, Rajiv Kumar, Consolato Sergi, Barbara Burwinkel. Int J Cancer 2006
19
22

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève,[...]. Lancet 2018
22

Immunotherapy for Melanoma.
Aya A Albittar, Omar Alhalabi, Isabella C Glitza Oliva. Adv Exp Med Biol 2020
10
22

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.
Ahmad Najem, Mohammad Krayem, Anne Perdrix, Joseph Kerger, Ahmad Awada, Fabrice Journe, Ghanem Ghanem. Anticancer Res 2017
24
11

Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive Disease.
Benjamin A Lerner, Latoya A Stewart, David P Horowitz, Richard D Carvajal. Oncology (Williston Park) 2017
23
11

Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics.
Philippe Marchetti, Pierre Guerreschi, Laurent Mortier, Jerome Kluza. Int J Cell Biol 2015
17
11

Glutaminolysis: A Hallmark of Cancer Metabolism.
Lifeng Yang, Sriram Venneti, Deepak Nagrath. Annu Rev Biomed Eng 2017
201
11

Lactate: a metabolic key player in cancer.
Franziska Hirschhaeuser, Ulrike G A Sattler, Wolfgang Mueller-Klieser. Cancer Res 2011
549
11

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer.
Egidio Iorio, Maria José Caramujo, Serena Cecchetti, Francesca Spadaro, Giulia Carpinelli, Rossella Canese, Franca Podo. Front Oncol 2016
22
11

The Succinate Receptor GPR91 Is Involved in Pressure Overload-Induced Ventricular Hypertrophy.
Lei Yang, Di Yu, Ran Mo, Jiru Zhang, Hu Hua, Liang Hu, Yu Feng, Song Wang, Wei-Yan Zhang, Ning Yin,[...]. PLoS One 2016
12
11

A New Classification Method of Metastatic Cancers Using a 1H-NMR-Based Approach: A Study Case of Melanoma, Breast, and Prostate Cancer Cell Lines.
Corentin Schepkens, Matthieu Dallons, Jonas Dehairs, Ali Talebi, Jérôme Jeandriens, Lise-Marie Drossart, Guillaume Auquier, Vanessa Tagliatti, Johannes V Swinnen, Jean-Marie Colet. Metabolites 2019
2
50



Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Annette S Little, Kathryn Balmanno, Matthew J Sale, Scott Newman, Jonathan R Dry, Mark Hampson, Paul A W Edwards, Paul D Smith, Simon J Cook. Sci Signal 2011
151
11

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
11

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
Teresa Amaral, Tobias Sinnberg, Friedegund Meier, Clemens Krepler, Mitchell Levesque, Heike Niessner, Claus Garbe. Eur J Cancer 2017
55
11

Metabolomics Applications in Precision Medicine: An Oncological Perspective.
Leonor Puchades-Carrasco, Antonio Pineda-Lucena. Curr Top Med Chem 2017
41
11

Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin.
Yogesh Rai, Priyanshu Yadav, Neeraj Kumari, Namita Kalra, Anant Narayan Bhatt. Biosci Rep 2019
10
11

Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH.
Eric L Allen, Danielle B Ulanet, David Pirman, Christopher E Mahoney, John Coco, Yaguang Si, Ying Chen, Lingling Huang, Jinmin Ren, Sung Choe,[...]. Cell Rep 2016
35
11

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells.
Franziska Baenke, Barbara Chaneton, Matthew Smith, Niels Van Den Broek, Kate Hogan, Haoran Tang, Amaya Viros, Matthew Martin, Laura Galbraith, Maria R Girotti,[...]. Mol Oncol 2016
94
11

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.
Thomas M Ashton, W Gillies McKenna, Leoni A Kunz-Schughart, Geoff S Higgins. Clin Cancer Res 2018
260
11

The Warburg Effect and the Hallmarks of Cancer.
Laurent Schwartz, Claudiu T Supuran, Khalid O Alfarouk. Anticancer Agents Med Chem 2017
146
11

Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
Lili Guo, Bo Zhou, Zhengqing Liu, Ying Xu, Hao Lu, Meng Xia, Ensong Guo, Wanying Shan, Gang Chen, Changyu Wang. Tumour Biol 2016
23
11

Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer.
J M Matés, J A Segura, M Martín-Rufián, J A Campos-Sandoval, F J Alonso, J Márquez. Curr Mol Med 2013
111
11

The MYCN oncogene and differentiation in neuroblastoma.
Ulrica K Westermark, Margareta Wilhelm, Anna Frenzel, Marie Arsenian Henriksson. Semin Cancer Biol 2011
89
11


Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Gábor Petővári, Titanilla Dankó, Ildikó Krencz, Zoltán Hujber, Hajnalka Rajnai, Enikő Vetlényi, Regina Raffay, Judit Pápay, András Jeney, Anna Sebestyén. Pathol Oncol Res 2020
8
12

Metastatic melanoma treatment: Combining old and new therapies.
Ryan J Davey, Andre van der Westhuizen, Nikola A Bowden. Crit Rev Oncol Hematol 2016
49
11

Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors.
Paola Corazao-Rozas, Pierre Guerreschi, Fanny André, Pierre-Elliott Gabert, Steve Lancel, Salim Dekiouk, Delphine Fontaine, Meryem Tardivel, Ariel Savina, Bruno Quesnel,[...]. Oncotarget 2016
42
11

Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer.
Jinlu Wang, Hongfei Ji, Xingjian Niu, Lei Yin, Yiran Wang, Yucui Gu, Dongbo Li, Han Zhang, Minghui Lu, Fengxia Zhang,[...]. Dis Markers 2020
2
50

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Jaekyoung Son, Costas A Lyssiotis, Haoqiang Ying, Xiaoxu Wang, Sujun Hua, Matteo Ligorio, Rushika M Perera, Cristina R Ferrone, Edouard Mullarky, Ng Shyh-Chang,[...]. Nature 2013
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.